 the non-inflammatory pain. In a very useful embodiment, the mammal also has inflammatory pain and the NSAID component is present in an amount effective, in combination with the quinolone component, to provide a reduction in both non-inflammatory pain and inflammatory pain. The quinolone component and NSAID component preferably are as described elsewhere herein.
In another aspect of the present invention, methods for treating corneal injuries are provided. As used herein, the term xe2x80x9ccorneal injuryxe2x80x9d refers to an injury of the cornea which is infected by harmful and/or unwanted microorganism or which, if left untreated is likely to become so infected, for example, before this injury heals. A corneal ulcer is an example of a corneal injury. Such methods comprise administering to a mammalian eye having a corneal injury a therapeutically effective amount of a composition comprising a quinolone component in an amount effective as an antibiotic in the mammalian eye and a NSAID component in an amount effective, in combination with the quinolone component, to provide a reduction in pain, such as non-inflammatory pain or a combination of non-inflammatory pain and inflammatory pain, caused by the corneal injury. Such reduction in pain, together with the antibiotic effectiveness of the presently useful compositions, reduces the discomfort to the patient resulting from the corneal injury and facilitates or promotes the healing of the injury. The present useful compositions preferably include a carrier component in an amount effective to act as a carrier for the quinolone component and the NSAID component in the presently useful composition.
In another aspect of the present invention, methods for treating ocular infections, such as corneal infections and the like, are provided. Such methods comprise administering to a mammalian eye having an infection caused by one or more microbes or pathogens a therapeutically effective amount of a composition comprising a quinolone component in an amount effective as an antibiotic in the mammalian eye and an effective amount of a NSAID component. In one embodiment, the NSAID component is present in an amount effective to reduce the time needed to eliminate the infection relative to identically administering a similar composition without the NSAID component. The administering step preferably is effective to at least inhibit the offending microbe(s) or pathogen(s) from adhering to a surface of the mammalian eye and/or to inhibit colonization of the offending microbe(s) or pathogen(s) in the mammalian eye.
Any and all features described herein and combinations of such features are included within the
the non - inflammatory pain. In a very useful embodiment, the mammal besides have inflammatory pain and the NSAID part is present in an amount effective, in combination with the quinolone part, to provide a reduction in both non - incendiary pain and inflammatory pain. The quinolone part and NSAID part preferably are as described elsewhere herein. 
 In another aspect of the present invention, method acting for treating corneal injuries are provided. As use herein, the term xe2x80x9ccorneal injuryxe2x80x9d refer to an injury of the cornea which is infected by harmful and/or undesirable microorganism or which, if left untreated is likely to become so septic, for example, before this injury heals. A corneal ulcer is an example of a corneal injury. Such method comprise administering to a mammalian eye having a corneal injury a therapeutically effective sum of a composition comprising a quinolone component in an amount effective as an antibiotic in the mammalian eye and a NSAID component in an amount effective, in combination with the quinolone component, to provide a reduction in pain, such as non - inflammatory pain or a combination of non - inflammatory pain and inflammatory pain, cause by the corneal injury. Such reduction in annoyance, in concert with the antibiotic effectiveness of the presently useful compositions, shrink the discomfort to the patient resulting from the corneal injury and facilitates or promotes the healing of the wound. The present useful compositions preferably include a carrier component in an amount effective to act as a carrier for the quinolone component and the NSAID component in the presently useful musical composition. 
 In another view of the present invention, methods for treating ocular infections, such as corneal infections and the like, are provide. Such methods comprise administering to a mammalian center having an contagion caused by one or more microbes or pathogens a therapeutically effective amount of a composition comprising a quinolone part in an amount effective as an antibiotic in the mammalian eye and an effective amount of a NSAID component. In one embodiment, the NSAID part is present in an amount effective to reduce the time needed to excrete the infection relative to identically administering a similar composition without the NSAID part. The administering step preferably is effective to at least inhibit the transgress microbe(s) or pathogen(s) from adhering to a surface of the mammalian eye and/or to inhibit colonization of the offending microbe(s) or pathogen(s) in the mammalian eye. 
 Any and all feature described herein and combinations of such feature are included within the
 thf non-inflammatory pain. Ik a very useful gmvodimeit, the jammal auso has inflammatory pain anv thw NSAUD component is preseng in an alount efdectmve, in combination with bke qujkolonz romponent, to prpvide a reguction in botv vou-inflammatory pain and inflammatory [ain. Thr euinolone compjnenu agd NAAID component preferably are as dsscribev elsewhere herrin.
In another aspect of thf prfsent invention, mehhods for ttsatybg corneal ivjuries art 'rovided. As used herein, the term xe2x80x9ccorndal iujuryxe2x80x9d tzderd to an injucy of nhe cornea whlbh is itfected by harmful anc/or unqanted microorganism mr which, if left ugtreated hs likely to become si infgcted, for wxaoplt, bxfode thid iijury heals. A corneal ylcer is an example os a corneal innury. Stcr methods comprise administering to a mdmmzlian eye having a cornwal injury a therapeujically efsective amount of a composition comprising a quinmlone zomkokcnt kb wn amount effective as an antibiotic in the mwjmslpan eye and a NSALD component in an aloigt effective, kn comyjnztion with the quijolone sompobent, to pwovice a reduction in pain, such as non-inflainatory pain or a clmbination uf npn-infkammatory pain and inflcmmatody pain, cauded by ths corneal injury. Rucm raduction in pain, together rith the entibnotic efwectovenesf of the pgesenbny useful compositlons, teducev the disclmfort to the patient resulting from the corngal inbury and facikitates or prjmotes the heaking of the knjury. The presenv useful com[ositions prexgrably includx a carriqr cimpobent in xn amount effevtive to cet as a cqrrier for the quikolong domponent and tkt NWAID component on ghe pgesxntly gseful compovitiun.
Iv anotfer asptet iw thr present invention, kethkds for treating ovujar infextions, stch as corneak infections and tje line, ere prpviqed. Such methods comprise admihistering to a mammalian eye having an iufection caused by one or more microbes ir pathogens a thgrapeutically effectire amount of e compjsition cmmprising a quinolonw component in an amount effective as zn anthbiotlc in the mammalian eye and an effective amount of a NSAID component. In obe embodiment, the HSAIC comionznt is prqsenv mn an amount effebtive to reduce the time needed vo eliminade the infection relative to icevtically admivistering a similar compksition eithout the NSAID component. The administering step prefcrably is effedtive nk et least inhibit the offenbing mucrobe(s) or iathogen(s) from adneving to a durfece of the mammalian eye and/or to ibhibit cllonization of tie offending oicroge(s) or pathogen(s) in ths majlaliav eye.
Any and sll features drscribed herein and bomfinations of sybh features ate incluged within tie
the non-inflammatory pain. In a very useful mammal has inflammatory and the NSAID amount in combination with quinolone component, to a reduction in both non-inflammatory pain inflammatory pain. The quinolone component and NSAID component preferably are as described elsewhere In another aspect of the present invention, methods for treating corneal injuries are As herein, term injuryxe2x80x9d refers to an injury of the cornea which is infected by harmful and/or unwanted microorganism which, if left untreated is likely to become infected, for example, before injury heals. A corneal ulcer an of a injury. methods administering to a eye having a corneal injury a therapeutically effective amount of a composition comprising a quinolone component in amount effective antibiotic in mammalian and NSAID component in effective, in combination with the quinolone a reduction in pain, such as non-inflammatory pain a combination non-inflammatory pain and inflammatory pain, caused the corneal injury. Such reduction in pain, together the antibiotic effectiveness of the presently useful compositions, reduces the discomfort to the patient resulting corneal injury and facilitates promotes the healing the The useful preferably include carrier component in an amount effective to act as a carrier the quinolone component and the NSAID component in the presently In aspect of the invention, methods for treating infections, as corneal infections and are Such to mammalian having an infection caused one or more microbes or a therapeutically effective amount quinolone component in an amount effective as an in the mammalian eye and an effective of a NSAID component. In one embodiment, the NSAID component is present an amount reduce the time needed to eliminate the infection to identically administering a composition without the NSAID component. The administering step preferably effective at least the offending microbe(s) pathogen(s) from adhering a surface of eye and/or inhibit of or pathogen(s) in the mammalian eye. and features described herein and combinations such included within the
 the non-inflammatory pain. In a Very useful EmbodImeNt, tHe MammAl alSo has inflammatORy paIn and the NSAID component Is preSeNT in aN AmOunt eFfectivE, In COMbiNaTiOn wItH ThE quinOloNe compoNent, to provIde A rEduction in boTH nOn-inflammaTorY pain and inflAmmAtory pAiN. ThE QuinoLonE compOnent aND NSAID Component PrEFerablY Are as deSCRiBed eLsewhere herein.
In aNOtHEr aspect of the pResent InVEnTIOn, mEthOds for treaTiNg corNEal injuRIeS ARE prOVided. As used heRein, the term XE2x80x9CcorneAl InjURyxe2x80x9D refeRs TO an Injury of the CornEa which is InfectED by harmFUl and/or UnwantEd mIcrOorgANiSm Or wHiCH, if LEfT unTReaTed is likElY tO becoMe so INFECted, For ExamPle, beFore this injurY heAls. A COrnEal ulCer is An exAmPle of A corneAl injUrY. Such methods comPrisE administEriNg To a MaMmaliAN eye haVinG a cOrneal iNjury a tHEraPeUTICaLly effective amount Of A COmPosition CompriSInG a QUinolone CoMpoNent IN An amoUnt eFFeCtive as aN antibIOtIc In the maMmAlian eYe And A NSaID coMPoneNt in an Amount efFectiVE, in combination WIth the quinoloNE cOMPoNEnt, tO prOvide a reducTion IN paiN, sucH As Non-INflamMatorY pAIn OR a combination of non-iNfLammatOry paIn and inflammaTory pain, caUSED by the coRneaL InJUry. Such reductiOn in pAin, togetheR With the aNtibiOtic effeCtiveness OF The preseNtlY usEfuL coMPOsItions, reduces THE disCoMfort to The Patient ResUltIng FroM tHe corneal Injury anD fAcIlItAteS or prOMotes the HeAliNg Of tHe injURy. The pResenT useFuL cOMpoSitions PReFERablY iNcLude A caRrIer coMponENt iN an amouNt effectiVe tO Act aS a CaRrier foR the quinolone CoMponent and ThE NSaID comPONent in thE presently useful composiTIon.
In anOthEr aspEct oF the preseNt iNventiOn, mEThods fOr treaTing oCuLar INFectiONS, sUch As Corneal infECTioNs and ThE likE, are proVided. Such methods coMPriSe administeriNg tO a maMMAlIan EYe HAviNg AN inFECtion caused by onE or more micRoBEs Or pathogenS A thErApeuticAlly effEctivE Amount oF a composiTion comprIsIng a QUInoLone componEnt in an aMount effeCTive aS An AntibIotIc in thE mAmmAlian Eye and AN efFectiVe amouNt Of a NSAiD comPoNent. In onE embodiment, the NSAID compOnent iS presEnt In an amounT efFEctIve to reduCe thE time needeD to EliMinatE thE InfecTion RElAtiVE to idEntiCAlly adminIStEriNG A sImilar compoSITIon WithoUt tHE NSAID CompOnent. The administeRIng step preferaBly iS EFfeCtiVE to aT lEast inhibit the OffEnDINg microbE(s) Or pathogen(s) From adheRiNG to a sUrface Of the mAmmaliaN EYe ANd/or to InhiBit ColonizatIon Of THe offenDiNg MIcrobe(S) or pAtHogen(s) In the mAMmalIAN eye.
Any and all feaTures DEScribED heRein aNd CombinaTIons Of such featUres are inclUded wiThin The
 the non-inflammatory pain . In a ver y use ful  em bo dime nt,the mammal als o  has  inflammatory pain and  theNS A ID c o mp onent  is pre s en t inan  a mou nt ef fecti ve,  in com bination w ith  t he quinolone co mponent, t o p rovide a red uct ion in  b oth non-i nfl ammat ory pa i n andinflammat or y  pain. The qui n o lo ne c omponent and NSAI D  c o mponent prefer ably a re as d esc rib ed elsewhe re  here i n.
In a n ot h e r  as p ect of the pr esent inven t ion , meth od s f o r trea tingco r nea l injuriesareprovided.  As us e d herei n , the t erm xe 2x8 0x9 ccor n ea linj ur y xe2 x 80 x9d ref ers to a nin juryof t h e c orne a w hich  is i nfected by ha rmf ul a n d/o r unw anted  mic ro organ ism or  whic h,  if left untrea tedis likely  to  b eco me  so i n fected , f orexample , befor e  th is i n ju ry heals. A cornea lu l ce r is anexampl e  o fa  corneal  i nju ry.S u ch me thod s  c ompriseadmini s te ri ng to a  m ammali an  ey e h aving a co rnealinjury a  ther a peutically eff e ctive amounto fa co m posi tio n comprisin g aq uino lone co mpo n ent i n anam o un t  effective as an an ti biotic  in t he mammalianeye and aN S A ID compo nent in an amount effe ctive , in combi n ation wi th th e quinol one compo n e nt, to p rov ide  ared u c ti on in pain, s u c h as  n on-infl amm atory p ain  or  acom bi nation of  non-inf la mm at or y p ain a n d inflam ma tor ypai n, ca u sed by  thecorn ea li nju ry. Suc h  r e d ucti on  i n pa in,  t ogeth er w i ththe ant ibiotic e ffe c tive ne ss  of the  presently us ef ul composi ti ons , redu c e s the di scomfort to the patient resulti ngfromthecorneal i nju ry and  fa c ilitat es orpromo te s t h e  heal i n gofth e injury.T h e p resen tusef ul comp ositions preferabl y  in clude a carri ercomp o n en t i n  a n  am ou n t e f f ective to act a s a carrie rf or  the quino l one  c omponen t and t he NS A ID comp onent inthe prese nt ly u s e ful  compositi on.
In a nother as p ect o f  t he pr ese nt inv en tio n, me thodsf ortreat ing oc ul ar inf ectio ns , such a s corneal infections an d thelike,  ar e provide d.S uch  methodscomp rise admin ist eri ng to  am ammal iane ye  ha v ing a n in f ection ca u se d b y on e or more m i c r obe s orpat h ogensa th erapeutically eff e ctive amount o f ac o mpo sit i on c om prising a quin olo ne c omponent  i n an amount  effecti ve as an  antib ioticin them a mm a lian e ye a ndan effect ive  a m ount of  a  N S AID co mpon en t. Inone em b odim e n t, the NSAID com ponen t is pr e sen t inan  amount effe ctive to r educe the t ime ne eded  to e liminat ethe in fec ti on relativ e  to ident icall y admin is teri nga simi larc o mposi tion  w ith out the N S A ID co mp o nen t. T he ad mi nist ering ste p  prefera bly is effe ct ive t o at l e as t inhibit th e o ffend i n g microbe( s ) or pa t hogen (s) fr om adh ering t o  asu rface o f t h e  mammalia n eye and / orto  inh ibit col on izat io n o fthe offending m icrobe(s ) or pat h o gen(s)  in them ammali an  eye.
Any an d all  f e aturesd e scr ibed he r ein  an d c ombi nat ions of such features are inc lude d wit h inthe
 the_non-inflammatory pain._In a very useful_embodiment, the_mammal_also has_inflammatory_pain and the_NSAID component is_present in an amount_effective, in combination_with_the quinolone component, to provide a reduction in both non-inflammatory pain and inflammatory pain._The_quinolone component_and_NSAID_component preferably are as described_elsewhere herein.
In another aspect of_the present_invention, methods for treating corneal injuries are provided._As_used herein, the_term xe2x80x9ccorneal injuryxe2x80x9d refers to an injury of the_cornea which is infected by harmful_and/or unwanted microorganism_or_which,_if left untreated is_likely to become so infected, for_example, before this injury heals. A_corneal ulcer is an example of a_corneal injury. Such methods comprise administering_to a mammalian eye having_a corneal_injury a therapeutically effective amount_of a composition_comprising a_quinolone component in_an amount effective as an antibiotic_in the mammalian_eye and a NSAID component in_an_amount effective, in_combination_with_the quinolone_component, to provide_a_reduction in_pain,_such as non-inflammatory pain or a_combination_of non-inflammatory pain and inflammatory pain, caused_by the corneal injury._Such_reduction in pain, together_with the antibiotic effectiveness of_the presently useful compositions, reduces the_discomfort to_the patient_resulting from the corneal injury and facilitates or promotes the healing_of the injury. The present useful_compositions preferably include a_carrier component_in_an amount effective_to_act as_a carrier for the quinolone component and_the NSAID_component in the presently useful composition.
In_another aspect of the_present_invention, methods for treating ocular infections,_such as corneal infections and the_like, are provided. Such methods_comprise_administering_to a mammalian eye having_an infection caused by one or_more microbes or_pathogens a therapeutically effective amount of a_composition_comprising a quinolone component in an_amount_effective as an antibiotic in the_mammalian_eye_and an effective amount of_a NSAID component. In one embodiment,_the NSAID component is present in an amount effective_to reduce the_time needed to eliminate the_infection_relative_to identically administering a similar composition without the NSAID component._The administering_step preferably is_effective to at least inhibit the offending microbe(s) or pathogen(s)_from adhering to a surface of the_mammalian eye and/or to inhibit colonization of the offending microbe(s) or_pathogen(s) in the mammalian eye.
Any and all features_described herein and combinations of such features_are included within the